Experienced in Squamous Cell Skin Carcinoma

Dr. Brian C. Baumann

Radiation Oncology
Springfield Clinic, Llp
2200 Wabash Ave, 
Springfield, IL 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Experienced in Squamous Cell Skin Carcinoma
Springfield Clinic, Llp
2200 Wabash Ave, 
Springfield, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Baumann is a Radiation Oncologist in Springfield, Illinois. Dr. Baumann is rated as an Experienced provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and Merkel Cell Carcinoma. Dr. Baumann is currently accepting new patients.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Squamous Cell Skin Carcinoma.

Specialties
Radiation Oncology
Licenses
Radiology in MO
Hospital Affiliations
Barnes Jewish Hospital
St Lukes Hospital
Memorial Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

SPRINGFIELD CLINIC, LLP
2200 Wabash Ave, Springfield, IL 62704
Other Locations
UROLOGY OF ST LOUIS INC
12855 N 40 Dr, Arch Cancer Care, Saint Louis, MO 63141
SPRINGFIELD CLINIC, LLP
701 N 1st St, Springfield, IL 62781
SPRINGFIELD CLINIC, LLP
567 N Westgate Ave, Jacksonville, IL 62650
SPRINGFIELD CLINIC, LLP
900 N 1st St, Springfield, IL 62702
SPRINGFIELD CLINIC, LLP
1025 S 6th St, Springfield, IL 62703
SPRINGFIELD CLINIC, LLP
775 Engineering Ave, Springfield, IL 62703
SPRINGFIELD CLINIC, LLP
600 N Main St, Taylorville, IL 62568
SPRINGFIELD CLINIC, LLP
100 Stahlhut Dr, Lincoln, IL 62656
UROLOGY OF ST LOUIS INC
6812 State Route 162 200, Maryville, IL 62062

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I/II Dose-escalation Study Evaluating the Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
A Phase I/II Dose-escalation Study Evaluating the Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
Enrollment Status: Recruiting
Publish Date: January 27, 2026
Intervention Type: Radiation
Study Phase: Phase 1/Phase 2
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone
Study Phase: Phase 3
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drug: Paclitaxel
Study Phase: Phase 1/Phase 2
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Procedure, Biological, Drug, Other, Radiation
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Durvalumab, Gemcitabine, Methotrexate, Vinblastine, Fluorouracil, Mitomycin C
Study Phase: Phase 2
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Enrollment Status: Terminated
Publish Date: April 12, 2022
Intervention Type: Other
Study Phase: Not Applicable
View 7 Less Clinical Trials

112 Total Publications

Analysis of Medicare Reimbursement Trends in Medical and Radiation Oncology.
Analysis of Medicare Reimbursement Trends in Medical and Radiation Oncology.
Journal: Practical radiation oncology
Published: April 01, 2025
Similar Doctors
Experienced in Squamous Cell Skin Carcinoma
Dr. Harold A. Yoon
Radiation Oncology
Experienced in Squamous Cell Skin Carcinoma
Dr. Harold A. Yoon
Radiation Oncology

Cancer Care Specialists Of Central Illinois Sc

210 W Mckinley Ave, Suite 1, 
Decatur, IL 
 (39.9 miles away)
217-877-9442
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Harold Yoon is a Radiation Oncologist in Decatur, Illinois. Dr. Yoon is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Familial Prostate Cancer, Small Cell Lung Cancer (SCLC), Prostate Cancer, and Lung Cancer. Dr. Yoon is currently accepting new patients.

Experienced in Squamous Cell Skin Carcinoma
Dr. Daniel J. Ferraro
Radiation Oncology
Experienced in Squamous Cell Skin Carcinoma
Dr. Daniel J. Ferraro
Radiation Oncology

Springfield Clinic, Llp

775 Engineering Ave, 
Springfield, IL 
 (2.7 miles away)
217-522-4300
Languages Spoken:
English
See accepted insurances

Daniel Ferraro is a Radiation Oncologist in Springfield, Illinois. Dr. Ferraro is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Laryngeal Cancer, Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, and ALK-Positive Non-Small Cell Lung Cancer.

Experienced in Squamous Cell Skin Carcinoma
Dr. Mary A. Depaz
Radiation Oncology
Experienced in Squamous Cell Skin Carcinoma
Dr. Mary A. Depaz
Radiation Oncology

Cancer Care Specialists Of Central Illinois Sc

210 W Mckinley Ave, Suite 2, 
Decatur, IL 
 (39.9 miles away)
217-876-4700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mary Depaz is a Radiation Oncologist in Decatur, Illinois. Dr. Depaz is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. Her top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Angiosarcoma, and Small Cell Lung Cancer (SCLC). Dr. Depaz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baumann's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile